FDA Adverse Event Malfunction Summary report: N

POWERLOC MAX POWER-INJECTIBLE INFUSION SET 19G X 0.75IN

MDR report key: 18374613 · Received December 21, 2023

Report

Report Number
3006260740-2023-05791
Event Type
Malfunction
Date Received
December 21, 2023
Date of Event
November 17, 2023
Report Date
March 5, 2024
Manufacturer
C.R. BARD, INC. (BASD) -3006260740
Product Code
FPA
UDI-DI
00801741047435
PMA / PMN Number
K153440
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
NJ, US
Reporter Occupation
OTHER HEALTH CARE PROFESSIONAL
Health Professional
Yes

Narratives

Additional Manufacturer Narrative · 0

H11: SECTION A THROUGH F - THE INFORMATION PROVIDED BY BD REPRESENTS ALL OF THE KNOWN INFORMATION AT THIS TIME. DESPITE GOOD FAITH EFFORTS TO OBTAIN ADDITIONAL INFORMATION, THE COMPLAINANT/REPORTER WAS UNABLE OR UNWILLING TO PROVIDE ANY FURTHER PATIENT, PRODUCT, OR PROCEDURAL DETAILS TO BD.

Additional Manufacturer Narrative · 0

H11: SECTION A THROUGH F - THE INFORMATION PROVIDED BY BD REPRESENTS ALL OF THE KNOWN INFORMATION AT THIS TIME. DESPITE GOOD FAITH EFFORTS TO OBTAIN ADDITIONAL INFORMATION, THE COMPLAINANT / REPORTER WAS UNABLE OR UNWILLING TO PROVIDE ANY FURTHER PATIENT, PRODUCT, OR PROCEDURAL DETAILS TO BD. THE COMPLAINT OF A DAMAGED INFUSION SET IS CONFIRMED; HOWEVER, THE ROOT CAUSE COULD NOT BE DETERMINED. TWO PHOTOGRAPHS OF INFUSION SETS WERE RETURNED FOR EVALUATION. ONE PHOTOGRAPH OF THREE 19G X 0.75¿ POWERLOC MAX KITS WAS ALSO RETURNED. AN INITIAL VISUAL OBSERVATION OF THE PHOTOGRAPHS SHOWED THE EXTENSION TUBING WAS BROKEN AT THE JUNCTION BETWEEN THE TUBE AND LUER CONNECTOR. EVIDENCE OF USE WAS OBSERVED ON THE SAMPLE. ALTHOUGH A BREAK IN THE EXTENSION TUBING WAS EVIDENT IN THE SUBMITTED PHOTOGRAPH, INSPECTION OF THE PHOTOGRAPH WAS INSUFFICIENT TO IDENTIFY THE CAUSE OF THE DAMAGE. CONSEQUENTLY, THIS COMPLAINT IS CONFIRMED AS ¿CAUSE UNKNOWN¿ AT THIS TIME. THIS COMPLAINT WILL BE RECORDED FOR FUTURE TRENDING AND MONITORING PURPOSES. H3 OTHER TEXT : EVALUATION FINDINGS ARE IN SECTION H.11.

Additional Manufacturer Narrative · 0

H11: SECTION A THROUGH F - THE INFORMATION PROVIDED BY BD REPRESENTS ALL OF THE KNOWN INFORMATION AT THIS TIME. DESPITE GOOD FAITH EFFORTS TO OBTAIN ADDITIONAL INFORMATION, THE COMPLAINANT / REPORTER WAS UNABLE OR UNWILLING TO PROVIDE ANY FURTHER PATIENT, PRODUCT, OR PROCEDURAL DETAILS TO BD. THE MANUFACTURER HAS RECEIVED THE SAMPLE AND WILL EVALUATE. RESULTS ARE EXPECTED SOON.

Description of Event or Problem · 0

NURSE REQUESTING THE PLASTIC MATERIALS USED FOR THE SAFESTEP AND MINILOC NEEDLES. STATES THEY HAVE NOTICED THAT THE PLASTIC TUBING IN THE SAFESTEP NEEDLE BREAKS DOWN WHEN INFUSING BLINATUMOMAB COMPARED TO THE MINILOC NEEDLE. SHE IS WONDERING IF THEY BOTH HAVE DIFFERENT PLASTIC MATERIALS. ALSO, INQUIRING IF THE MINILOC AND SAFESTEP NEEDLES ARE DEHP FREE. MS&S RESPONSE: INFORMED THE NEEDLE FOR THE MINILOC NEEDLE IS 304 STAINLESS STEEL, WITH ACRYLIC ADHESIVE AND SILICONE OIL. THE TUBING FOR THE MINILOC NEEDLE IS PVC (POLYVINYL CHLORIDE). OTHER MATERIALS INCLUDE POLYPROPYLENE, POLYETHERIMIDE, ABS (ACRYLONITRILE BUTADIENE STYRENE), RIGID PVC, AND LDPE (LOW-DENSITY POLYETHYLENE). THE FLUID PATH MATERIALS ARE FLEXIBLE PVC, RIGID PVC, ABS, 304 STAINLESS STEEL, UV-CURING ACRYLIC ADHESIVE, AND SILICONE. THE NEEDLE FOR THE SAFESTEP IS 304 STAINLESS STEEL, WITCH ACRYLIC ADHESIVE AND SILICONE OIL. THE TUBING FOR THE SAFESTEP NEEDLE IS PVC (POLYVINYL CHLORIDE). OTHER MATERIALS INCLUDE ABS (ACRYLONITRILE BUTADIENE STYRENE), RIGID PVC, AND POLYCARBONATE. THE FLUID PATH MATERIALS ARE FLEXIBLE PVC, RIGID PVC, ABS, POLYCARBONATE, SILICONE, UV-CURE ACRYLIC ADHESIVE, AND 304 STAINLESS STEEL. BOTH THE MINILOC AND SAFESTEP NEEDLES AND PACKAGING ARE DEHP FREE. CHEMOTHERAPY (BLINATUMOMAB) HAD INFUSED THROUGH THE DEVICE. EVENT DIRECTLY INVOLVED A PATIENT. SINCE THE TUBING WAS CRACKED, THE CHEMOTHERAPY LEAKED OUT OF THE LINE AND ONTO THE PATIENT. NO IMMEDIATE HARM WAS NOTED. THE NURSES HAD TO PROPERLY DISPOSE OF THE CLOTHING AND BEDDING THAT THE CHEMOTHERAPY LEAKED ONTO. THEY HAD TO RE-ACCESS THE PATIENT WITH A NEW NEEDLE AND ASK THE PHARMACY FOR A NEW CHEMOTHERAPY PREPARATION.

Description of Event or Problem · 0

NURSE REQUESTING THE PLASTIC MATERIALS USED FOR THE SAFESTEP AND MINILOC NEEDLES. STATES THEY HAVE NOTICED THAT THE PLASTIC TUBING IN THE SAFESTEP NEEDLE BREAKS DOWN WHEN INFUSING BLINATUMOMAB COMPARED TO THE MINILOC NEEDLE. SHE IS WONDERING IF THEY BOTH HAVE DIFFERENT PLASTIC MATERIALS. ALSO, INQUIRING IF THE MINILOC AND SAFESTEP NEEDLES ARE DEHP FREE. MS&S RESPONSE: INFORMED THE NEEDLE FOR THE MINILOC NEEDLE IS 304 STAINLESS STEEL, WITH ACRYLIC ADHESIVE AND SILICONE OIL. THE TUBING FOR THE MINILOC NEEDLE IS PVC (POLYVINYL CHLORIDE). OTHER MATERIALS INCLUDE POLYPROPYLENE, POLYETHERIMIDE, ABS (ACRYLONITRILE BUTADIENE STYRENE), RIGID PVC, AND LDPE (LOW-DENSITY POLYETHYLENE). THE FLUID PATH MATERIALS ARE FLEXIBLE PVC, RIGID PVC, ABS, 304 STAINLESS STEEL, UV-CURING ACRYLIC ADHESIVE, AND SILICONE. THE NEEDLE FOR THE SAFESTEP IS 304 STAINLESS STEEL, WITCH ACRYLIC ADHESIVE AND SILICONE OIL. THE TUBING FOR THE SAFESTEP NEEDLE IS PVC (POLYVINYL CHLORIDE). OTHER MATERIALS INCLUDE ABS (ACRYLONITRILE BUTADIENE STYRENE), RIGID PVC, AND POLYCARBONATE. THE FLUID PATH MATERIALS ARE FLEXIBLE PVC, RIGID PVC, ABS, POLYCARBONATE, SILICONE, UV-CURE ACRYLIC ADHESIVE, AND 304 STAINLESS STEEL. BOTH THE MINILOC AND SAFESTEP NEEDLES AND PACKAGING ARE DEHP FREE. CHEMOTHERAPY (BLINATUMOMAB) HAD INFUSED THROUGH THE DEVICE. EVENT DIRECTLY INVOLVED A PATIENT. SINCE THE TUBING WAS CRACKED, THE CHEMOTHERAPY LEAKED OUT OF THE LINE AND ONTO THE PATIENT. NO IMMEDIATE HARM WAS NOTED. THE NURSES HAD TO PROPERLY DISPOSE OF THE CLOTHING AND BEDDING THAT THE CHEMOTHERAPY LEAKED ONTO. THEY HAD TO RE-ACCESS THE PATIENT WITH A NEW NEEDLE AND ASK THE PHARMACY FOR A NEW CHEMOTHERAPY PREPARATION.

Description of Event or Problem · 0

NURSE REQUESTING THE PLASTIC MATERIALS USED FOR THE SAFESTEP AND MINILOC NEEDLES. STATES THEY HAVE NOTICED THAT THE PLASTIC TUBING IN THE SAFESTEP NEEDLE BREAKS DOWN WHEN INFUSING BLINATUMOMAB COMPARED TO THE MINILOC NEEDLE. SHE IS WONDERING IF THEY BOTH HAVE DIFFERENT PLASTIC MATERIALS. ALSO, INQUIRING IF THE MINILOC AND SAFESTEP NEEDLES ARE DEHP FREE. MS&S RESPONSE: INFORMED THE NEEDLE FOR THE MINILOC NEEDLE IS 304 STAINLESS STEEL, WITH ACRYLIC ADHESIVE AND SILICONE OIL. THE TUBING FOR THE MINILOC NEEDLE IS PVC (POLYVINYL CHLORIDE). OTHER MATERIALS INCLUDE POLYPROPYLENE, POLYETHERIMIDE, ABS (ACRYLONITRILE BUTADIENE STYRENE), RIGID PVC, AND LDPE (LOW-DENSITY POLYETHYLENE). THE FLUID PATH MATERIALS ARE FLEXIBLE PVC, RIGID PVC, ABS, 304 STAINLESS STEEL, UV-CURING ACRYLIC ADHESIVE, AND SILICONE. THE NEEDLE FOR THE SAFESTEP IS 304 STAINLESS STEEL, WITCH ACRYLIC ADHESIVE AND SILICONE OIL. THE TUBING FOR THE SAFESTEP NEEDLE IS PVC (POLYVINYL CHLORIDE). OTHER MATERIALS INCLUDE ABS (ACRYLONITRILE BUTADIENE STYRENE), RIGID PVC, AND POLYCARBONATE. THE FLUID PATH MATERIALS ARE FLEXIBLE PVC, RIGID PVC, ABS, POLYCARBONATE, SILICONE, UV-CURE ACRYLIC ADHESIVE, AND 304 STAINLESS STEEL. BOTH THE MINILOC AND SAFESTEP NEEDLES AND PACKAGING ARE DEHP FREE. CHEMOTHERAPY (BLINATUMOMAB) HAD INFUSED THROUGH THE DEVICE. EVENT DIRECTLY INVOLVED A PATIENT. SINCE THE TUBING WAS CRACKED, THE CHEMOTHERAPY LEAKED OUT OF THE LINE AND ONTO THE PATIENT. NO IMMEDIATE HARM WAS NOTED. THE NURSES HAD TO PROPERLY DISPOSE OF THE CLOTHING AND BEDDING THAT THE CHEMOTHERAPY LEAKED ONTO. THEY HAD TO RE-ACCESS THE PATIENT WITH A NEW NEEDLE AND ASK THE PHARMACY FOR A NEW CHEMOTHERAPY PREPARATION.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
2153237 POWERLOC MAX POWER-INJECTIBLE INFUSION SET 19G X 0.75IN SET, ADMINISTRATION, INTRAVASCULAR FPA C.R. BARD, INC. (BASD) -3006260740 N/A ASGTFC116 00801741047435

Patients

Seq Age Sex Outcome Treatment
1 NA Unknown Other